Search
PF-ILD_Infographic.pdf
786210196-001-PF-ILD_Media_Backgrounder.pdf
Wireframes_UI About us - Blueprint for building Levels 1-3.pdf
Infographic RA-ILD
Building Lasting Partnerships for a Better Future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
ACR19 SENSCIS Mycophenolate
ACR Congress 2019 abstract analysing a subgroup of patients in the SENSCIS® trial in patients with SSc-ILD by use of mycophenolate at baseline
ACR19 demographic trial
ACR Congress 2019 abstract analysing the safety and tolerability of nintedanib in SSc-ILD patients in the SENSCIS® trial in a demographic subgroup
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Pride Month 2023: Why belonging matters – to all of us
LGBTIQ+ community members and their allies share how we can create a welcoming and inclusive culture where everyone feels heard, accepted and appreciated.
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients